{"id":"W2902530914","doi":"10.1093/annonc/mdy517","title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":795,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Triple-negative breast cancer; Pembrolizumab; Metastatic breast cancer; Cohort; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003641351,0.001235571,0.001083077,0.0002669206,0.0005740515,0.0009245723,0.0007530693,0.0007297248,0.002586259],"category_scores_gemma":[0.001840995,0.0005066855,0.001353921,0.0003193238,0.0004137648,0.0006658806,0.0005611927,0.001704123,0.000821373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006296188,"about_ca_system_score_gemma":0.001372346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000905972,"about_ca_topic_score_gemma":0.001837354,"domain_scores_codex":[0.9992005,0.0004266856,0.00005355786,0.0001303673,0.00008992687,0.00009887014],"domain_scores_gemma":[0.9985958,0.0001773957,0.0003662698,0.0002635112,0.0001445584,0.0004525594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7142141,0.03088536,0.1554912,0.001236721,0.007492959,0.0006581828,0.0003936525,0.001971697,0.02411815,0.0005495457,0.01731583,0.04567248],"study_design_scores_gemma":[0.4607644,0.2219109,0.2733721,0.0003324873,0.006806856,0.002634196,0.000399335,0.002918233,0.006428078,0.0006163318,0.02365525,0.0001618212],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875889,0.001974488,0.0005771194,0.0002993918,0.00006980715,0.001849448,0.005954804,0.0000421429,0.00164385],"genre_scores_gemma":[0.9763615,0.001595751,0.001801407,0.000890275,0.0002114602,0.002332142,0.01490511,0.00003661271,0.001865744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003641351,"threshold_uncertainty_score":0.01925755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07573474290946053,"score_gpt":0.4318296695631981,"score_spread":0.3560949266537375,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}